Current Headlines

  1. Hengrui Pharma Partners With Medidata To Accelerate Global Drug Research

    Medidata announced that Hengrui Pharma, one of China’s largest sponsors, recently adopted Medidata Cloud, the Intelligent Platform for Life Sciences, to accelerate global drug research

  2. Mission Therapeutics And AbbVie Sign DUBs Collaboration In Alzheimer’s And Parkinson’s Disease

    Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie (“AbbVie”), a research-based global biopharmaceutical company, recently announced a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease

  3. Anti-Malaria Drugs Have Shown Promise In Treating Cancer, And Now Researchers Know Why

    Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor

  4. Priority Review Granted To BeiGene’s New Drug Applications For Zanubrutinib And Tislelizumab In China

    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that Center for Drug Evaluation of China’s National Medical Product Administration (NMPA, formerly known as CFDA) has granted priority review status to the New Drug Applications (NDAs) for the company’s investigational BTK inhibitor zanubrutinib in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and for its investigational anti-PD-1 antibody tislelizumab in patients with R/R classical Hodgkin’s lymphoma (cHL)

  5. Exelixis’ Partner Ipsen Receives European Commission Approval For CABOMETYX (Cabozantinib) Tablets For The Treatment Of Hepatocellular Carcinoma In Adults Previously Treated With Sorafenib

    Exelixis, Inc. recently announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib

  6. Exscientia Builds 'Full Stack' AI-Driven Drug Discovery Capabilities Through Acquisition Of Kinetic Discovery

    Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company

  7. Lilly Submits New Drug Application To The FDA For Lasmiditan For Acute Treatment Of Migraine, Receives Breakthrough Therapy Designation For Emgality™ (galcanezumab-gnlm) For Prevention Of Episodic Cluster Headache

    Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment of migraine with or without aura in adults

  8. Charles River Laboratories Continues Commitment To Oncology Drug Discovery

    Charles River Laboratories International, Inc. recently announced new additions to the Tumor Model Compendium. Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research

  9. 'Waltzing' Nanoparticles Could Advance Search For More Effective Drug Delivery Methods

    Indiana University researchers have discovered that drug-delivering nanoparticles attach to their targets differently based upon their position when they meet -- like ballroom dancers who change their moves with the music

  10. Researchers Report New Methods To Identify Alzheimer’s Drug Candidates That Have Anti-Aging Properties

    Old age is the greatest risk factor for many diseases, including Alzheimer’s disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds